What Moderna's FY2025 10-K says: 12 signals
Moderna filed its latest 10-K with the SEC on Feb 20, 2026. It discusses capacity constraint, capex increase and compliance burden.
Public (MRNA)Biotechnology Research5,001 to 10,000 employeesmodernatx.comLinkedIn
- Filed
- Feb 20, 2026
- Period
- FY2025
- Fiscal year end
- 12/31
- Filings
- 1
10-K · latest 9
What Moderna's 10-K filings say
- SEC EDGAR
10-K · FY2025
Filed · Fiscal year ends 12/31 · 12 signals
Moderna launching cost reduction initiative through 2027 using AI and digital tools
The company explicitly plans to leverage artificial intelligence (AI) and digital tools to improve cost efficiency across manufacturing, R&D, and SG&A.
AIdigital tools
Moderna flags production difficulties for its personalized cancer therapy, intismeran.
The company's intismeran product requires a unique and complex manufacturing process for each patient, creating a significant risk of production challenges.
mRNAMerckRecordati
Moderna expands global manufacturing with new facilities in the UK, Canada, and Australia.
To support new product launches and ensure local supply, Moderna has built three new international facilities and is streamlining its global network.
mRNA
Moderna to leverage AI and digital tools for major cost efficiency drive in 2026-2027
As a core strategic priority, Moderna is focused on delivering cost efficiency across manufacturing, R&D, and SG&A.
AIdigital tools
Moderna faced FDA 'Refusal-to-File' letter for flu vaccine candidate mRNA-1010
This highlights a critical need for robust regulatory compliance and data management solutions to prevent future delays.
Moderna acknowledges dependency on single-source suppliers for critical components.
The company's reliance on single-source suppliers for components and materials poses a significant risk to its development and commercialization efforts.
Moderna deepens collaboration with Merck on mRNA cancer therapy across eight clinical trials
Moderna is advancing its individualized cancer therapy, intismeran, in a major collaboration with Merck, with eight Phase 2 and Phase 3 trials now underway.
Merck
New COVID vaccine mNEXSPIKE launched in Q3 2025, now leading US retail product
Moderna's new COVID vaccine, mNEXSPIKE, has quickly become its leading product in the U.S.
Moderna incurred net losses in 2024 and 2025, expects trend to continue
The company is facing significant profitability challenges, reporting net losses for two consecutive years and anticipating more in the future.
Showing 9 of 12 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Moderna with the Signal API
One POST /v1/companies/enrich call with modernatx.com returns Moderna 10-K signals (sec-10k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"modernatx.com","signal_types":["sec-10k"],"limit":20}'Same industry
10-K at related companies
Questions about Moderna 10-K
When did Moderna file its latest 10-K?
What does Moderna's latest 10-K say about cost reduction?
Where can I find Moderna's annual report?
Source. Annual reports (Form 10-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .